Stockreport

Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share

Daxor Corporation  (DXR) 
NASDAQ:AMEX Investor Relations: daxor.com/investors
PDF Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- [Read more]